# EA2251 (NCT07765433)

> Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer

No report yet. It can be ordered.

- Drugs tested: ivonescimab
- Indication: advanced biliary tract cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07765433
- Phase: PHASE2, PHASE3
- Status: NOT_YET_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Locally Advanced Biliary Tract Adenocarcinoma; Locally Advanced Extrahepatic Cholangiocarcinoma; Locally Advanced Intrahepatic Cholangiocarcinoma; Locally Advanced Unresectable Gallbladder Adenocarcinoma; Metastatic Biliary Tract Adenocarcinoma; Metastatic Extrahepatic Cholangiocarcinoma; Metastatic Gallbladder Adenocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Biliary Tract Adenocarcinoma; Unresectable Extrahepatic Cholangiocarcinoma; Unresectable Intrahepatic Cholangiocarcinoma
- Interventions: Biospecimen Collection; Cisplatin; Computed Tomography; Durvalumab; Gemcitabine Hydrochloride; Ivonescimab; Magnetic Resonance Imaging; Pembrolizumab
- Enrollment: 336
- Primary outcome: Overall survival (OS)

## Some of the questions raised in the 9 indexed sources

_Automated from all 9 indexed sources (Oct 2026 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether EA2251 in a US population matches the HARMONi-GI1 findings from a China-only trial
- When EA2251 sites will open and enrolment will begin
- Whether EA2251 can support US approval of ivonescimab in first-line biliary tract cancer, and how soon

## Indexed commentary on EA2251 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused first edition, $750. Buy the first edition with create_order on https://mcp.erudio.com/mcp (product "first_edition", report "NCT07765433", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/ea2251-nct07765433. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07765433", "email": "<work email>"}; the inbox owner confirms by the emailed link.
